PALI vs. GOVX, MIRA, BTAI, CYTH, APRE, BFRG, CARM, MEIP, AFMD, and PIRS
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), Aprea Therapeutics (APRE), Bullfrog AI (BFRG), Carisma Therapeutics (CARM), MEI Pharma (MEIP), Affimed (AFMD), and Pieris Pharmaceuticals (PIRS). These companies are all part of the "pharmaceutical products" industry.
Palisade Bio vs.
GeoVax Labs (NASDAQ:GOVX) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings, media sentiment and community ranking.
Palisade Bio's return on equity of -148.51% beat GeoVax Labs' return on equity.
GeoVax Labs has a beta of 3.29, suggesting that its share price is 229% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by insiders. Comparatively, 3.3% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
GeoVax Labs presently has a consensus price target of $14.20, suggesting a potential upside of 539.64%. Palisade Bio has a consensus price target of $23.00, suggesting a potential upside of 1,423.18%. Given Palisade Bio's higher probable upside, analysts clearly believe Palisade Bio is more favorable than GeoVax Labs.
Palisade Bio has higher revenue and earnings than GeoVax Labs.
GeoVax Labs received 13 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 95.83% of users gave GeoVax Labs an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote.
In the previous week, Palisade Bio had 3 more articles in the media than GeoVax Labs. MarketBeat recorded 5 mentions for Palisade Bio and 2 mentions for GeoVax Labs. GeoVax Labs' average media sentiment score of 0.53 beat Palisade Bio's score of -0.19 indicating that GeoVax Labs is being referred to more favorably in the media.
Summary
GeoVax Labs beats Palisade Bio on 9 of the 16 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PALI) was last updated on 1/22/2025 by MarketBeat.com Staff
